Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CYCC | Common Stock | Award | $0 | +21.2K | +109.47% | $0.00 | 40.6K | Jun 30, 2023 | Direct | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CYCC | Stock Option (right to buy) | Award | $0 | +42.4K | $0.00 | 42.4K | Jun 30, 2023 | Common Stock | 42.4K | $0.59 | Direct | F2 |
Id | Content |
---|---|
F1 | The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024. |
F2 | These securities were granted to Dr. Schwartz for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. |